(Reuters) - The safety of Avandia, Glaxo's second-best-selling drug, with global sales of 1.6 billion pounds last year, came into question in May, when a U.S. analysis linked Avandia to a 43 percent higher chance of having a heart attack.
That triggered a plunge in prescriptions and some investors feared the drug would be pulled from the all-important U.S. market. Worldwide sales in the three months to June dropped to 349 million pounds from 477 million a year ago, the company reported last week.
Read more at Reuters.com Hot Stocks News
That triggered a plunge in prescriptions and some investors feared the drug would be pulled from the all-important U.S. market. Worldwide sales in the three months to June dropped to 349 million pounds from 477 million a year ago, the company reported last week.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment